Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879553 | 0.92 | ACACB (0.32) | HSD11B1ACACB | |
| SCHEMBL590295 | 0.88 | CETP (0.35) | — | |
| SCHEMBL588844 | 0.84 | CETP (0.34) | — | |
| SCHEMBL12879784 | 0.83 | DRD3 (0.32) | — | |
| SCHEMBL16503379 | 0.83 | HSD11B1 (0.35) | HSD11B1CYP1A2CYP2D6GSK3BACACB | |
| SCHEMBL1202336 | 0.83 | HSD11B1 (0.35) | HSD11B1CYP1A2CYP2D6GSK3BACACB | |
| SCHEMBL8046502 | 0.83 | HSD11B1 (0.35) | HSD11B1CYP1A2CYP2D6GSK3BACACB | |
| SCHEMBL8058848 | 0.80 | DRD2 (0.32) | GSK3B | |
| SCHEMBL8049914 | 0.80 | HSD11B1 (0.35) | HSD11B1CYP1A2CYP2D6GSK3BACACB | |
| SCHEMBL12872291 | 0.79 | GRM5 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090626-B2 | Piperazino-dihydrothienopyrimidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090626-B2 | Piperazino-dihydrothienopyrimidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20130274264-A1 | PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| US-20130274264-A1 | PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-17 | — | — | US | disclosed |
| US-8486948-B2 | Piperazinodihydrothienopyrimidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-8486948-B2 | Piperazinodihydrothienopyrimidine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110046096-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046096-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2009050236-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046096-A1 | NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | DPYD, PRDX5, PRDX1 | HSD11B1 4135/4885CYP1A2 907/4885CYP2D6 91/4885 |
| US-20130274264-A1 | PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES | PDE4A, PDE12, PDE4B | HSD11B1 151/4885CYP1A2 272/4885CYP2D6 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.